BB&T Securities’s Endocyte, Inc. Common Stock ECYT Stock Holding History

BB&T Securities’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-20,750	Closed	-$368K	–	1656
2018 Q3	$368K	Hold	20,750	–	–	﹤0.01%	1236
2018 Q2	$286K	Hold	20,750	–	–	﹤0.01%	1299
2018 Q1	$188K	Hold	20,750	–	–	﹤0.01%	1417
2017 Q4	$88K	Hold	20,750	–	–	﹤0.01%	1415
2017 Q3	$29K	Sell	20,750 -500	-2%	-$697	﹤0.01%	1387
2017 Q2	$31K	Buy	+21,250	New	+$45.6K	﹤0.01%	1371

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

BB&T Securities's ECYT Position: Q4 2018 in Review

BB&T Securities sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 20,750 shares — an estimated $368K sold.

BB&T Securities first reported a position in ECYT in Q2 2017 and held it in 6 quarters. The position peaked at $368K in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

BB&T Securities reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
BB&T Securities sold 20,750 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $368K.
BB&T Securities first reported a position in Endocyte, Inc. Common Stock in Q2 2017 and held it in 6 quarters.
BB&T Securities's Endocyte, Inc. Common Stock position peaked at $368K in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on BB&T Securities's 13F filing for Q4 2018, filed 4 Feb 2019.